Michael J. Labarre Sells 10,000 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) Stock

Halozyme Therapeutics, Inc. (NASDAQ:HALO) SVP Michael J. Labarre sold 10,000 shares of the business’s stock in a transaction dated Tuesday, February 25th. The stock was sold at an average price of $58.05, for a total transaction of $580,500.00. Following the sale, the senior vice president now owns 185,453 shares in the company, valued at $10,765,546.65. This trade represents a 5.12 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Halozyme Therapeutics Stock Performance

Halozyme Therapeutics stock opened at $59.15 on Friday. The firm’s 50 day simple moving average is $54.28 and its 200-day simple moving average is $54.73. Halozyme Therapeutics, Inc. has a fifty-two week low of $37.73 and a fifty-two week high of $65.53. The company has a market cap of $7.28 billion, a P/E ratio of 17.24, a price-to-earnings-growth ratio of 0.42 and a beta of 1.25. The company has a debt-to-equity ratio of 4.14, a current ratio of 7.80 and a quick ratio of 9.15.

Halozyme Therapeutics (NASDAQ:HALO) last posted its earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 EPS for the quarter, topping the consensus estimate of $1.17 by $0.02. The company had revenue of $298.01 million during the quarter, compared to the consensus estimate of $285.74 million. Halozyme Therapeutics had a net margin of 43.74% and a return on equity of 157.78%. As a group, equities research analysts predict that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current year.

Hedge Funds Weigh In On Halozyme Therapeutics

Large investors have recently bought and sold shares of the stock. Heck Capital Advisors LLC acquired a new position in Halozyme Therapeutics during the 4th quarter valued at $29,000. CBIZ Investment Advisory Services LLC bought a new stake in Halozyme Therapeutics in the 4th quarter valued at $29,000. Smartleaf Asset Management LLC grew its holdings in shares of Halozyme Therapeutics by 29.2% in the 4th quarter. Smartleaf Asset Management LLC now owns 871 shares of the biopharmaceutical company’s stock worth $42,000 after purchasing an additional 197 shares during the last quarter. Venturi Wealth Management LLC bought a new stake in shares of Halozyme Therapeutics in the 4th quarter worth about $69,000. Finally, Parkside Financial Bank & Trust grew its holdings in shares of Halozyme Therapeutics by 21.8% in the 4th quarter. Parkside Financial Bank & Trust now owns 1,800 shares of the biopharmaceutical company’s stock worth $86,000 after purchasing an additional 322 shares during the last quarter. 97.79% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

HALO has been the topic of a number of research reports. Benchmark reiterated a “buy” rating and issued a $75.00 target price on shares of Halozyme Therapeutics in a report on Thursday, February 20th. HC Wainwright boosted their target price on shares of Halozyme Therapeutics from $70.00 to $72.00 and gave the stock a “buy” rating in a report on Wednesday, February 19th. JMP Securities boosted their target price on shares of Halozyme Therapeutics from $72.00 to $73.00 and gave the stock a “market outperform” rating in a report on Friday, November 1st. Wells Fargo & Company dropped their target price on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating on the stock in a report on Monday, January 13th. Finally, Piper Sandler boosted their target price on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a “neutral” rating in a report on Friday, January 10th. Four equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $62.78.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.